Unlocking the potential of atractylenolide II: Mitigating non-alcoholic fatty liver disease through farnesoid X receptor-endoplasmic reticulum stress interplay. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.